Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.2% during the fourth quarter, HoldingsChannel reports. The fund owned 1,053,709 shares of the life sciences company’s stock after selling 23,466 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Illumina were worth $140,807,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the 4th quarter valued at approximately $32,000. Assetmark Inc. boosted its stake in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina during the fourth quarter worth $45,000. Finally, Lee Danner & Bass Inc. purchased a new position in Illumina in the fourth quarter worth $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on ILMN shares. Guggenheim decreased their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada lowered their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 12th. Canaccord Genuity Group reduced their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and lowered their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Stock Down 5.4 %

Shares of NASDAQ ILMN opened at $82.83 on Thursday. The firm’s 50 day moving average price is $105.03 and its 200 day moving average price is $127.40. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market cap of $13.12 billion, a P/E ratio of -10.79, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.